Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Mar 22:2:18.
doi: 10.1186/1758-5996-2-18.

Low-density lipoprotein particle size in hepatic steatosis and metabolic syndrome

Affiliations

Low-density lipoprotein particle size in hepatic steatosis and metabolic syndrome

Dal-Sik Kim et al. Diabetol Metab Syndr. .

Abstract

Background: Hepatic steatosis (HS), the most frequent liver disorder, was reported to be an independent predictor of cardiovascular disease. HS, if combined with the metabolic syndrome (MetS), might have a synergistic effect on low-density lipoprotein (LDL) particle size.

Methods: Carotid intima-media thickness (IMT) and plaque formation, and HS were diagnosed ultrasonographically, and the MetS was diagnosed using the ATP III criteria in 274 healthy workers (mean age +/- SD, 43.5 +/- 7.1 yrs). LDL particle size was measured with density gradient ultracentrifugation, and subfractions were classified as large, buoyant LDL I (27.2 to approximately 28.5 nm) and small, dense LDL III (24.2~25.5). All participants were grouped into three categories: control, subjects with HS alone and those with both HS and the MetS.

Results: The subjects with HS alone were 84 (30.7%), whereas those with HS and the MetS were 46 (16.8%). LDL peak particle sizes showed significant negative correlations with carotid mean IMTs. LDL peak particle size and LDL I (%) decreased significantly in the HS, showing the lowest values in the subjects with both HS and the MetS, and their association was independent, even adjusted for potential confounders. LDL III also showed independent associations across the groups.

Conclusion: HS alone was more prevalent than HS combined with the MetS in general population. For the patients with HS alone, LDL particle size and carotid atherosclerosis were found to fall in the middle of the control and those with both HS and the MetS.

PubMed Disclaimer

Figures

Figure 1
Figure 1
LDL peak particle size and subfractions in hepatic steatosis (HS) according to its combination with/without the metabolic syndrome (MetS). A. Mean values (with 95% CIs) of LDL peak particle size (nm), B. Large, buoyant LDL subfraction I (%), and C. Small, dense LDL subfraction III (%): All three values showed significant linear associations with the three categories (P < 0.001). * P < 0.01, **P < 0.001; compared with the control (Bonferroni comparison). P < 0.05, †† P < 0.01; compared with the HS alone.
Figure 2
Figure 2
Scatter plots of carotid intima-media thickness (IMT) and LDL peak particle size. A. A scatter plot of both CCA mean IMT and LDL peak particle size, r = -0.14, P = 0.021; B. A scatter plot of both ICA mean IMT and LDL peak particle size, r = -0.16, P = 0.010.

Similar articles

References

    1. Neglected global epidemics: Three growing threats. Chapter 6. Geneva: World Health Organization; 2003. The world health report 2003 - Shaping the future.
    1. Yach D, Hawkes C, Gould CL, Hofman KJ. The Global Burden of Chronic Diseases: Overcoming Impediments to Prevention and Control. JAMA. 2004;291(21):2616–2622. doi: 10.1001/jama.291.21.2616. - DOI - PubMed
    1. Lorenzo C, Williams K, Hunt KJ, Haffner SM. Trend in the Prevalence of the Metabolic Syndrome and Its Impact on Cardiovascular Disease Incidence: The San Antonio Heart Study. Diabetes Care. 2006;29(3):625–630. doi: 10.2337/diacare.29.03.06.dc05-1755. - DOI - PubMed
    1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–1053. doi: 10.2337/diacare.27.5.1047. - DOI - PubMed
    1. Tolonen H, Keil U, Ferrario M, Evans A. for the WHOMP. Prevalence, awareness and treatment of hypercholesterolaemia in 32 populations: results from the WHO MONICA Project. Int J Epidemiol. 2005;34(1):181–192. doi: 10.1093/ije/dyi056. - DOI - PubMed

LinkOut - more resources